Downloaded from: justpaste.it/7xm6r
Covid-19: Sinovac vaccine shows 78% efficacy in Brazil after data confusion The protection rate, confirmed by Sao Paulo state officials, was derived from Sinovac’s most advanced final-phase trials in Brazil involving about 13,000 participants
The vaccine developed by China’s Sinovac Biotech Ltd. was found to be 78% effective against Covid-19 in late-stage trials in Brazil, the most definitive evidence so far on the shot’s efficacy after previous data sparked doubt and confusion. The protection rate, confirmed by Sao Paulo state officials, was derived from Sinovac’s most advanced final-phase trials in Brazil involving about 13,000 participants. Coming after data was withheld at a progress update in late December, the rate is still below the roughly 95% effectiveness seen in cutting-edge mRNA
vaccines developed by Pfizer Inc. and Moderna Inc. and being deployed in the U.S. Sinovac’s CoronaVac vaccine was 78% effective in preventing mild cases of Covid-19 and 100% effective against severe and moderate infections, said Dimas Covas, director of the Butantan Institute that partnered with Sinovac to produce the shot locally. The trial saw about 220 participants infected — 160 in the placebo group while almost 60 received the vaccine, Covas said.